Bakhsh Allah, Kim Bosung, Ishamri Ismail, Choi Seongho, Li Xiangzi, Li Qiang, Hur Sun Jin, Park Sungkwon
Department of Food Science and Biotechnology, College of Life Science, Sejong University, Seoul 05006, Korea.
Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad 44000, Pakistan.
Food Sci Anim Resour. 2025 Jan;45(1):145-164. doi: 10.5851/kosfa.2024.e122. Epub 2025 Jan 1.
Cell-based meat (CBM) technology is a highly promising alternative to traditional animal agriculture, with considerable advantages in terms of sustainability, animal welfare, and food security. Nonetheless, CBM's successful commercialization is dependent on efficiently dealing with several critical concerns, including ensuring biological, chemical, and nutritional safety as well as navigating the global regulatory framework. To ensure CBM's biological safety, detecting and mitigating any potential hazards introduced during the manufacturing process is crucial. Concerns include microbial contamination, the utilization of animal-derived growth media, and the risk of viral or prion infection. Similarly, chemical hazards include residues from growth media, scaffolding materials, and other bioprocessing agents. For consumer acceptance, CBM's nutritional qualities should be comparable to those of conventional meat, indicating adequate protein content, essential amino acids, vitamins, and minerals. Additionally, CBM's safety in terms of allergenicity and the presence of anti-nutritional factors must be rigorously assessed. Advances in cell culture techniques and biomanufacturing methods are requisite to achieving high-quality CBM with desirable nutritional attributes. The regulatory framework for CBM is actively expanding, with significant regional variations. Singapore is currently the only country that has received approval for the market placement of CBM, although the United States has developed a regulatory structure involving the United States Department of Agriculture and Food and Drug Administration. As CBM holds great potential as a sustainable and ethical alternative to conventional meat, addressing challenges related to biological and chemical safety, nutritional quality, and regulatory approval is essential for its successful market integration.
细胞培育肉(CBM)技术是传统畜牧业极具前景的替代方案,在可持续性、动物福利和食品安全方面具有显著优势。尽管如此,CBM的成功商业化取决于有效解决几个关键问题,包括确保生物、化学和营养安全,以及应对全球监管框架。为确保CBM的生物安全,检测和减轻制造过程中引入的任何潜在危害至关重要。相关问题包括微生物污染、动物源生长培养基的使用以及病毒或朊病毒感染风险。同样,化学危害包括生长培养基、支架材料和其他生物加工剂的残留。为获得消费者认可,CBM的营养品质应与传统肉类相当,即蛋白质含量、必需氨基酸、维生素和矿物质充足。此外,必须严格评估CBM在致敏性和抗营养因子方面的安全性。细胞培养技术和生物制造方法的进步是实现具有理想营养特性的高质量CBM的必要条件。CBM的监管框架正在积极扩展,存在显著的地区差异。新加坡是目前唯一已获批将CBM投放市场的国家,不过美国已建立了由美国农业部和食品药品监督管理局参与的监管架构。由于CBM作为传统肉类的可持续且符合伦理的替代方案具有巨大潜力,应对与生物和化学安全、营养品质及监管审批相关的挑战对其成功融入市场至关重要。